23andMe therapeutics group to better understand common and rare diseases

March 13, 2015
A new therapeutics group aims to use human genetic data as the starting point for identifying new therapies for both common and rare diseases.

Personal genetics company 23andMe (Mountain View, CA) has created a new therapeutics group that aims to use human genetic data as the starting point for identifying new therapies for both common and rare diseases. The group, in connection with the company's research platform, will lead to better understanding the biological mechanisms of disease and accelerating the discovery of novel treatments through human genetics.

Related: 23andMe direct-to-consumer genetic test receives FDA clearance

Leading the new group will be Richard Scheller, Ph.D., whom the company appointed as its chief science officer and head of therapeutics. Scheller retired in December 2014 from a distinguished 14-year career as an executive at Genentech, where he was the executive VP of research and early development. There, he led the company's research strategy, drug discovery, business development, and early drug development activities (through proof of concept in the clinic) around oncology, immunology, neuroscience, and infectious disease.

When Scheller assumes his post at 23andMe in April 2015, he will help build a dedicated research and development team.

Update: In April 2015, the company also appointed Robert Gentleman, Ph.D., as its VP of computational biology, a role in which Gentleman will focus on the exploration of how the human genetic and trait data in the company's database can be used to identify new therapies for disease. He will collaborate with Scheller and others to help the newly formed therapeutics group utilize data analytics and theoretical models to identify trends and ultimately advance the drug research and discovery process.


Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Chroma Customer Spotlight - Dr. David Warshaw, About his Lab

Nov. 27, 2023
David Warshaw, Professor and Chair of Molecular Physiology and Biophysics at the University of Vermont (UVM), walks us through his lab. Learn about his lab’s work with the protein...

Catalog of Filters and Filter Sets

Nov. 27, 2023
This price list provides information about the filter sets Chroma Technology has created for the multitude of fluorochromes that are typically used in epi-fluorescence microscopy...

Handbook of Optical Filters for Fluorescence Microscopy

Nov. 27, 2023
Fluorescence microscopy requires optical filters that have demanding spectral and physical characteristics. These performance requirements can vary greatly depending on the specific...

Custom & OEM Filter Design Brochure

Nov. 27, 2023
At Chroma Technology, we consider ourselves to be partners with our customers. With 25 years of experience serving the scientific, biomedical and photonics communities, we know...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!